Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 2
1980 2
1981 2
1982 4
1983 2
1984 2
1985 1
1987 3
1989 4
1990 4
1991 3
1992 8
1993 3
1994 5
1995 3
1996 3
1997 5
1998 4
1999 16
2000 12
2001 9
2002 18
2003 28
2004 34
2005 27
2006 42
2007 30
2008 33
2009 34
2010 40
2011 53
2012 51
2013 58
2014 44
2015 48
2016 46
2017 33
2018 31
2019 27
2020 14
2021 23
2022 15
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 15570079

732 results

Results by year

Filters applied: . Clear all
Page 1
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M. Brandes AA, et al. J Clin Oncol. 2004 Dec 1;22(23):4779-86. doi: 10.1200/JCO.2004.06.181. J Clin Oncol. 2004. PMID: 15570079 Clinical Trial.
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini S, Ermani M; Gruppo Italiano Cooperativo di Neuro-Oncologia. Brandes AA, et al. J Clin Oncol. 2004 May 1;22(9):1598-604. doi: 10.1200/JCO.2004.11.019. J Clin Oncol. 2004. PMID: 15117981 Clinical Trial.
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Prados MD, Yung WK, Fine HA, Greenberg HS, Junck L, Chang SM, Nicholas MK, Robins HI, Mehta MP, Fink KL, Jaeckle KA, Kuhn J, Hess KR, Schold SC Jr; North American Brain Tumor Consortium study. Prados MD, et al. Neuro Oncol. 2004 Jan;6(1):33-7. doi: 10.1215/S1152851703000309. Neuro Oncol. 2004. PMID: 14769138 Free PMC article. Clinical Trial.
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS. Reardon DA, et al. Cancer. 2005 Oct 1;104(7):1478-86. doi: 10.1002/cncr.21316. Cancer. 2005. PMID: 16088964 Free article. Clinical Trial.
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, Grunnet K, Ask A, Costa JC, Kristiansen C, Thomsen C, Poulsen HS, Lassen U. Hofland KF, et al. Acta Oncol. 2014 Jul;53(7):939-44. doi: 10.3109/0284186X.2013.879607. Epub 2014 Jan 23. Acta Oncol. 2014. PMID: 24456504 Clinical Trial.
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, Amistà P, Gardiman M, Labianca R, Bianchini C, Ermani M, Reni M. Brandes AA, et al. Cancer Chemother Pharmacol. 2009 Sep;64(4):769-75. doi: 10.1007/s00280-009-0926-8. Epub 2009 Jan 24. Cancer Chemother Pharmacol. 2009. PMID: 19169684 Free PMC article. Clinical Trial.
732 results